dasatinib + BMS-833923

Dasatinib + BMS-833923 is an investigational **combination therapy** consisting of dasatinib, a multi-targeted tyrosine kinase inhibitor approved for chronic myeloid leukemia (CML), and BMS-833923, an investigational small molecule inhibitor of Smoothened (SMO) in the Hedgehog signaling pathway. - **Dasatinib** is an oral small molecule that inhibits BCR-ABL and Src-family kinases, disrupting leukemogenic signaling in Philadelphia chromosome–positive leukemias. - **BMS-833923 (XL139)** is an orally bioavailable, potent antagonist of SMO, blocking Hedgehog pathway signaling implicated in various cancers including CML. The combination is designed to target both the tyrosine kinase signaling and cancer stem cell persistence via Hedgehog pathway inhibition. The combination has been evaluated for safety, tolerability, and efficacy in clinical studies in patients with CML[1][3][5][7].

Other names

dasatinib plus BMS-833923dasatinib + XL139